CECCON, MONICA
 Distribuzione geografica
Continente #
NA - Nord America 2.369
EU - Europa 1.271
AS - Asia 455
SA - Sud America 4
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 4.105
Nazione #
US - Stati Uniti d'America 2.329
DE - Germania 282
IT - Italia 237
CN - Cina 204
IE - Irlanda 190
SE - Svezia 180
SG - Singapore 121
UA - Ucraina 89
GB - Regno Unito 83
RU - Federazione Russa 75
HK - Hong Kong 44
CA - Canada 40
AT - Austria 37
VN - Vietnam 26
FI - Finlandia 24
FR - Francia 24
IN - India 23
BE - Belgio 17
TR - Turchia 16
DK - Danimarca 14
ID - Indonesia 7
PL - Polonia 7
JP - Giappone 6
IR - Iran 5
BG - Bulgaria 4
BR - Brasile 3
NL - Olanda 3
ES - Italia 2
EU - Europa 2
KR - Corea 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
CL - Cile 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
RO - Romania 1
SC - Seychelles 1
YE - Yemen 1
Totale 4.105
Città #
Ann Arbor 502
Frankfurt am Main 211
Fairfield 207
Chandler 206
Woodbridge 206
Dublin 187
Houston 146
Milan 140
Wilmington 136
Ashburn 108
Dearborn 107
Jacksonville 89
Seattle 87
Singapore 79
New York 78
Cambridge 74
Princeton 53
Nanjing 47
Hong Kong 44
Vienna 36
Altamura 24
Lawrence 23
Shanghai 22
Nanchang 21
Beijing 19
Brussels 17
Lachine 15
San Diego 15
Santa Clara 15
Boardman 14
Fremont 13
Göttingen 12
Guangzhou 10
Norwalk 10
Falls Church 9
Hangzhou 9
Lissone 9
Andover 8
Helsinki 8
Los Angeles 8
Ottawa 8
Edmonton 7
Jakarta 7
Jiaxing 7
Lodz 7
Pune 7
Taizhou 7
Hebei 6
Kunming 6
Shenyang 6
Toronto 6
Hefei 5
Jinan 5
Kiev 5
Kocaeli 5
London 5
Monza 5
Taku 5
Tianjin 5
Bucha 4
Cagliari 4
Changsha 4
Dong Ket 4
Fürstenwalde 4
Motta Di Livenza 4
Ningbo 4
Zhengzhou 4
Bonndorf 3
Boston 3
Cinisello Balsamo 3
Haikou 3
Nürnberg 3
Redmond 3
Trento 3
Acton 2
Bradford 2
Carate Brianza 2
Castiglione Delle Stiviere 2
Catania 2
Changchun 2
Chicago 2
Chiswick 2
Daejeon 2
Delhi 2
Desio 2
Kilburn 2
Lanzhou 2
Lynnwood 2
Maarssen 2
Mississauga 2
Mountain View 2
Paris 2
Plovdiv 2
Quart de Poblet 2
Rome 2
Taiyuan 2
Torino 2
University Park 2
Washington 2
Wuhan 2
Totale 3.243
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 349
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 279
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 262
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 230
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 209
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 201
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 195
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 192
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 192
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 185
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 172
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 158
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 157
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 155
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 138
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 123
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 122
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 122
Crizotinib-resistan NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors 120
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 114
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 106
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 106
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 97
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 82
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 81
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 63
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 41
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 38
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 33
Totale 4.322
Categoria #
all - tutte 13.882
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.882


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020703 0 0 61 76 72 101 126 63 84 51 53 16
2020/2021642 34 37 60 82 54 76 50 59 40 59 32 59
2021/2022353 27 33 24 13 30 40 20 25 18 39 32 52
2022/2023849 83 244 88 88 60 114 8 58 52 20 19 15
2023/2024523 16 18 24 25 58 169 101 12 36 9 2 53
2024/2025181 67 114 0 0 0 0 0 0 0 0 0 0
Totale 4.322